Department of Medical Oncology and Hematology, Melanoma Medical Oncology Unit.
Department of Medical Oncology and Hematology, Immunotherapy and Innovative Therapeutics Unit.
Melanoma Res. 2021 Apr 1;31(2):178-180. doi: 10.1097/CMR.0000000000000715.
Immune-checkpoint inhibitors (ICIs) exposed the oncology community to novel immune-related adverse events (irAEs). Here, we report on a retrospective analysis of patients with melanoma who developed an ICI-related, unilateral, acute and peripheral facial nerve paralysis (Bell's palsy).We retrospectively reviewed all the cases of ICI-related Bell's palsy in patients with melanoma treated at our institution from January 2015 to January 2020. A total of five cases of ICI-related Bell's palsy were identified. Median age was 63 years. Median time-to-onset of Bell's palsy from ICIs initiation was 15 weeks. Four patients were treated with prednisone alone, whereas one patient was treated with prednisone plus valaciclovir. All the patients completely recovered from Bell's palsy without neurological sequelae. In melanoma patients treated with ICIs, Bell's palsy is a rare, neurologic irAE with a favorable outcome following administration of oral corticosteroids.
免疫检查点抑制剂（ICI）使肿瘤学界接触到新的免疫相关不良反应（irAE）。在这里，我们报告了一项回顾性分析，该分析涉及在我们机构接受治疗的患有黑色素瘤的患者出现的与 ICI 相关的单侧、急性和周围性面神经麻痹（贝尔氏麻痹）。我们回顾性地审查了 2015 年 1 月至 2020 年 1 月期间在我们机构接受治疗的患有黑色素瘤的患者中出现的所有与 ICI 相关的贝尔氏麻痹病例。共发现 5 例与 ICI 相关的贝尔氏麻痹。中位年龄为 63 岁。从 ICI 开始到贝尔氏麻痹发作的中位时间为 15 周。4 例患者单独使用泼尼松治疗，而 1 例患者使用泼尼松联合伐昔洛韦治疗。所有患者均完全从贝尔氏麻痹中康复，无神经后遗症。在接受 ICI 治疗的黑色素瘤患者中，贝尔氏麻痹是一种罕见的神经系统 irAE，在给予口服皮质类固醇后预后良好。
